Table Graph
   

ivermectin - versus control - for COVID 19 outpatients pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.93 [0.54, 1.59]< 10%4 studies (4/-)60.8 %lownot evaluable highcrucial-
hospitalization or death 0.77 [0.47, 1.28]< 10%3 studies (3/-)84.0 %lownot evaluable highcrucial-
clinical deterioration 0.94 [0.77, 1.15]< 10%3 studies (3/-)72.5 %lownot evaluable highimportant-
clinical improvement 1.07 [0.98, 1.17]> 10%2 studies (2/-)93.1 %lownot evaluable highimportant-
clinical improvement (21-day) 1.28 [0.79, 2.10]> 10%1 study (1/-)84.1 %NAnot evaluable important-
clinical improvement (28-day) 1.07 [0.97, 1.18]> 10%1 study (1/-)91.0 %NAnot evaluable important-
clinical improvement (time to event analysis only) 1.07 [0.98, 1.17]> 10%2 studies (2/-)93.1 %lownot evaluable highimportant-
hospitalization 0.80 [0.60, 1.06]< 10%4 studies (4/-)94.3 %lownot evaluable highimportant-
mechanical ventilation 1.34 [0.30, 6.03]< 10%1 study (1/-)35.2 %NAnot evaluable important-
Recovery (time to event analysis only) 1.02 [0.92, 1.13]> 10%1 study (1/-)64.7 %NAnot evaluable important-
viral clearance 0.92 [0.77, 1.09]> 10%1 study (1/-)17.3 %NAnot evaluable important-
viral clearance by day 14 0.76 [0.45, 1.28]> 10%1 study (1/-)15.0 %NAnot evaluable important-
viral clearance by day 7 0.93 [0.79, 1.09]> 10%2 studies (2/-)18.5 %lownot evaluable highimportant-

safety endpoints 00

serious adverse events 1.00 [0.14, 7.17]< 10%1 study (1/-)50.0 %NAnot evaluable important-
adverse events 1.00 [0.20, 5.07]< 10%1 study (1/-)50.0 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons